| abstract |
The present disclosure relates to methods of treating, preventing or ameliorating a TH17- or CSF1-mediated disease or disorder such as cancer, immunological disorders, and obesity by administering to a patient in need thereof a therapeutically effective amount of a FASN inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. |